Royalty Pharma Q2 Portfolio Receipts +20% to $727M; raises FY 2025 guidance

Royalty Pharma plc

2025-Q2 EPS reported $0.62 revenue$1,146,912,000

Portfolio Receipts $727M (+20% YoY); Royalty Receipts $672M (+11%), driven by Voranigo, Trelegy, Evrysdi, Tremfya.
Raised FY 2025 Portfolio Receipts guidance to $3.05B-$3.15B (was $2.975B-$3.125B).
Capital deployment of $595M in Q2; $1B in share repurchases in H1 2025 (31M shares).
Completed acquisition of external manager RP Management in May, making Royalty Pharma an integrated company.
Entered up to $2B funding arrangement with Revolution Medicines, including $1.25B synthetic royalty on daraxonrasib.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.